BiotechTube
SIWA Therapeutics

SIWA Therapeutics

San Diego, United States· Est.
siwatherapeutics.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $30M

Overview

SIWA Therapeutics is an early-stage biotech focused on the emerging field of senolytics—therapies that clear senescent or 'zombie' cells. The company's platform centers on antibodies designed to target advanced glycation end products (AGEs), which are biomarkers on senescent cells, offering a potential new approach for treating age-related conditions like pancreatic cancer. A recent preclinical study published in Scientific Reports, in collaboration with TGen/City of Hope, demonstrated that its lead candidate, SIWA318H, could slow pancreatic tumor growth by reshaping the tumor microenvironment. The company is privately held and currently in the preclinical development phase.

OncologyAge-related Diseases

Technology Platform

Antibody platform targeting Advanced Glycation End-products (AGEs) on senescent cells for selective clearance (senolysis).

Funding History

2
Total raised:$30M
Series A$25M
Seed$5M

Opportunities

The senolytic market addresses the root cause of multiple age-related diseases and is poised for significant growth.
A successful proof-of-concept in pancreatic cancer, a high-unmet-need area, could validate the platform and enable expansion into larger indications like fibrosis, neurodegeneration, and other cancers.
The antibody modality may offer advantages in specificity and dosing over first-generation small molecule senolytics.

Risk Factors

High scientific risk as the novel AGE-targeting mechanism is unproven in humans.
Intense competition in the rapidly evolving senolytic space from better-funded entities.
Financial risk due to dependency on future capital raises to advance the costly preclinical and clinical development pathway.

Competitive Landscape

The senolytic competitive landscape includes companies like Unity Biotechnology (small molecules), Calico (backed by Alphabet), and numerous academic spin-offs. SIWA differentiates by focusing on an antibody-based approach targeting AGEs, aiming for greater specificity. However, it competes with larger players with broader pipelines and deeper resources.

More companies in Biologics / Biosimilars →More companies in United States →